Tinea pedis
Drug research and approvals for tinea pedis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 4 studies of tinea pedis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 4
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates…NCT07898475 · Not reported · Dr. Amara Safdar · starts Oct 2, 2026
- A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by DermatophytesNCT07668999 · Phase 1 · Sinomune Pharmaceutical Co., Ltd · starts Mar 31, 2027
- Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional StudyNCT07245667 · Phase 2 · Propedix, Inc. · starts Dec 30, 2024
- Atmospheric Pressure Cold Plasma for Moderate-to-severe Tinea PedisNCT07056660 · Not applicable · Shenyang Medical College · starts Jul 25, 2025
Approved 12
- NaftifineSqualene monooxygenase inhibitor
- KetoconazoleCytochrome P450 51 inhibitor
- EconazoleCytochrome P450 51 inhibitor
- LuliconazoleCytochrome P450 51 inhibitor
- ClotrimazoleCytochrome P450 51 inhibitor
- OxiconazoleCytochrome P450 51 inhibitor
- GriseofulvinTubulin inhibitor
- MiconazoleCytochrome P450 51 inhibitor
- CiclopiroxIron chelating agent
- SulconazoleCytochrome P450 51 inhibitor
- SertaconazoleCytochrome P450 51 inhibitor
- Tolnaftate
Phase 3 3
- TerbinafineSqualene monooxygenase inhibitor
- Dapaconazole
- FluconazoleCytochrome P450 51 inhibitor
Phase 2 11
- Nitric oxideSoluble guanylate cyclase activator
- ItraconazoleCytochrome P450 51 inhibitor
- IsotretinoinRetinoic acid receptor agonist
- PrednicarbateGlucocorticoid receptor agonist
- OctenidineAntiseptic
- Berdazimer sodiumReleases NO, antimicrobial
- BifonazoleLanosterol 14-alpha demethylase inhibitor
- OteseconazoleLanosterol 14-alpha demethylase inhibitor
- OxygenEssential for cellular homeostasis
- Nitrogen
- Water
Phase 1 or earlier 4
- ButenafineSqualene monooxygenase inhibitor
- AlbaconazoleLanosterol 14-alpha demethylase inhibitor
- Sodium lauryl sulfate
- AN-2718
How its trials ended
67 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 11 whose ending is known, 45% met their primary endpoint, 0% missed it and 55% stopped early.
- Completed, result not reported4973%
- Status unknown69%
- Met its primary endpoint57%
- Stopped: other or unclear34%
- Stopped: lack of efficacy23%
- Ongoing11%
- Stopped: enrollment or feasibility11%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jun 29, 2016 | A blinded placebo controlled clinical trial to evaluate fungicidal activity with the topical application of nitric oxide releasing solution (NORS) in subjects…Nitric oxide releasing solution | Nitric Solutions Inc | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA